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Cochrane reviews are considered by many to be the “gold standard” or the final word in medical conversation on a topic. We
explored the eleven most relevant Cochrane reviews on herbal medicine and identified that frequently herbal medicines in the
included studies had not been sufficiently well characterised. If data on the effects of the plant parts are unavailable, effects of co-
active ingredients need to be considered and the plausibility of the study medications for the specific indications discussed. Effect
sizes calculated from exploratory studies would be best used to determine the sample sizes required for future confirmatory studies,
rather than as definitive reports of intervention effects. Reviews should be comprehensive, including discussion of putative adverse
events and possible drug interactions.We suggest that the guidelines for preparing Cochrane reviews be revised and offer assistance
in this task.
1. Introduction
The Cochrane Collaboration was established in 1993 as an
international network that now includes more than 28,000
people from more than 100 countries. The aim of the Co-
chrane Collaboration is to help health care providers, policy-
makers, and patients and their advocates and carers, to
make well-informed decisions about health care based on
the best available research evidence. Collaboration members
prepare, update, and promote “Cochrane reviews”—presently
about 5000 reviews are published in “The Cochrane Library”
(http://www.cochrane.org/about-us). The combination of
high quality work, conservative approaches to clinical deci-
sion-making, and open access publication has led to Co-
chrane being regarded as the final word in the medical
debate on a topic (i.e., gold standard, http://www.hsl.virginia
.edu/collections/ebm/aboutcochrane.cfm).
This standard may hold true for Cochrane reviews
on medical interventions including synthetic medications.
Herbal medicines, however, differ from chemical entities in
so far as they contain many ingredients (sometimes huge
numbers) that may have additive, synergistic, or partially or
fully antagonistic activities if they are co-active [1]. Resultant
effect is caused by “the active principle” of a herbal medicine,
that is, the combination of all active ingredients. If herbal
medicines are mixed, interactions may increase, making it
more difficult to understand the complexity of the resultant
effect. Authorities including the World Health Organization
and the European Medicines Agency (EMA) have pub-





The aim of this study was to explore new or updated
Cochrane reviews on herbal medicines for quality of report-
ing as an exercise to evaluate whether these publications
represent the best evidence. CONSORTguidelines for clinical
trials are the reporting standards recommended by the
Cochrane Collaboration [2].The recommended quality items
to be considered when reporting trials on herbal medicines
are summarized in the elaborated CONSORT statement that
has been published in 2006 [2].
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2. Methods
The Cochrane Database of Systematic Reviews “Issue 1 of 12,
January 2013” was searched using the term “herbal medicine”
as “Title, Abstract, or Keywords,” sorted by relevance (not
alphabetical or date). Two authors (Sigrun Chrubasik and
Julia Vlachojannis) extracted the data independently, record-
ing the number of studies with confirmatory study design or
intention-to-treat (ITT) analysis as a proportion of included
studies. Confirmatory studies were defined as those that
tested hypotheses and include a priori power and sample
size calculations (a power, or alpha level, of 80% (90%)
being associated with a 20% (10%) risk of Type II error, or
failure rate to detect a difference, beta level). ITT analysis
includes data from all possible participants, even those who
did not complete the intervention. Missing data are replaced
either by inserting baseline values or carrying forward the
last values, in order not to favour the intervention over
the control. Other details extracted were the duration of
the studies, outcome measures considered, number and
types of herbal medicines studied, and the herbal medicine
characteristics (plant parts stated, dose per day, in case of
extract the drug extract ratio and solvent, and content of
marker substances in the daily doses). Disagreements in data
extraction were resolved by discussion and consensus (all
authors).
3. Results
There were 102 reviews on “herbal medicine” identified
from 7694 records of title, abstract, and keywords in the
Cochrane library. Reviews were sorted by relevance, and
we selected the top eleven reviews for analysis (we had
planned to include the 10 most relevant reviews, but one
of these had zero articles included, thus we extended our
examination to include the next most relevant review). Most
of these reviews included studies investigatingChinese herbal
medicines (see Table 1). The plant parts used to prepare
the study medications and the daily doses of the herbal
medicines were rarely stated; likewise in case of extracts,
drug: extract ratios, and solvents, and for only few of the
herbal medicines were the quantities of marker substance(s)
per day given. Table 2 summarizes the trial quality details of
the data extraction. The reviews included zero (no studies;
see [10]) to 75 clinical studies (see [3]). Most studies were
of exploratory study design (𝑛 = 251). Only nine studies
had confirmatory study designs. Not all outcome measures
selected in the herbal medicine trials and reviews appeared
to be meaningful or logical. For example, duration of the
included studies did not exceed 6 months (mean duration
across all studies was 2.6 months) in one of the reviews
that reported mortality as primary outcome measure [6].
Similarly, despite short mean observation periods of 54 days
or 2 to 3 months, mortality or cardiovascular events were
chosen as primary outcome measure in two other reviews
[4, 13]. Plausibility for the plant parts used for specific
indications was not reported or discussed in any review;
neither were putative interactions and adverse events given
consideration.
4. Discussion
4.1. Characterisation of the Study Medication. The World
Health Organisation (WHO) recommends that the man-
ufacturing procedure of medicinal plant parts should be
described in detail (http://apps.who.int/medicinedocs/en/d/
Jh2984e/). Identification of the plant part and, where pos-
sible, assay of the plant preparation should be reported. If
identification of an active principle is not possible, it may
be sufficient to identify a characteristic substance or mixture
of substances (e.g., “chromatographic fingerprint”) to ensure
consistent quality of the preparation, such that the study
may be repeated with an “essentially similar” product [14].
Without this information, study results can be attributed only
to the plant part used in the individual study and cannot be
generalized because starting materials may vary considera-
bly in the composition of the active principle. Declara-
tion of marker substances for every plant part included in
a product may help manufacturers to produce somewhat
similar products; however, marker substances were stated
in only 8 of the 326 included herbal medicines in this
exercise. Another possibility is to prepare the herbal products
according to the Guideline of Good Manufacturing Prac-
tice (http://ec.europa.eu/health/documents/eudralex/vol-4/
index en.htm). In the review on herbal medicines for the
treatment of irritable bowel syndrome (IBS) [3] only two of
the 75 herbalmedicineswere prepared according to theWHO
recommendation and commercially available: IberogastR [15]
and Padma LaxR (http://www.swissmedic.ch/bewilligungen/
00009/00011/index.html?lang=de, see Betriebsbewillungen).
We cannot determine whether comparable quality stand-
ards are considered in patented Chinese herbal products
(see Table 1). For most Chinese herbal medicines, neither
the Latin binomial name of the plant and the part of the
plant, nor the dose used, were reported. For example, the
composition of the mixture “Daming,” used for lowering
elevated serum cholesterol [13], is described as consisting of
Rheum palmatum, Cassia obtusifolia, Salvia miltiorrhiza, and
Panax ginseng in the ratio of 12 : 12 : 6 : 1 [16]. These plant
parts were not stated in the publication of the clinical trial,
nor were they included or discussed in the review. Based on
common usage, we might assume that the roots of rhubarb
and ginseng, the fruit or leaf of Senna (Cassia), and the herb
(whole, above-ground plant) of sage were used.Three of these
plant parts contain toxic compounds (hydroxyanthracene
glycosides, monoterpenes; see section on adverse events),
but the lack of details in the study included in the Cochrane
review means that we cannot be sure about the quantity of
toxic components in the tested study medication Daming.
Likewise, the study medication “Xiaozhiling” has been
described as “a mixture of herbs” [13]. The only Xiaozhiling
formulation we found detailed in the public domain was
for injection into tumours (http://www.gp-tcm.org/wp-
content/uploads/2009/11/D5.4-Vol-III-FINAL.pdf?rs file key
=9133909644e22b12f07b2e994153490). We cannot be cer-
tain whether the product used for the treatment of hyper-
cholesterolaemia [13] was essentially similar. In some studies,
herbalism is practiced in a dynamic fashion—that is, up
to 23 different herbal medicines have been administered
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Table 1: The eleven most relevant Cochrane reviews extracted for the most important details of herbal medication characteristics.
Reference Origin of herbal Herbal medicine characteristics
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Chronic neck pain Chinese
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Stated in 𝑛 = 37
up to 23 PP
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1 European Stated in 𝑛 = 1
Stated in
all
DER: drug extract ratio; &one containing an additional alkaloid; #extract Egb761 is produced according to GMP from Ginkgo leaf; §one study investigated an
isolated compound; $two external medications containing additional synthetic compounds; %eight patented Chinese products.
concomitantly (see Table 1) and the formulae changed in the
course of the study [11]. The results achieved with original
and changed formulations cannot be considered together
because they provide different active principles.
According to the CONSORT checklist, reporting such
information, including the Latin names, plant parts, doses,
and marker substances, is mandatory. Correct identification
of plants and use of nomenclature are also required. For
example, in reviewing herbal medicines for low back pain,
Gagnier et al. [5] attributed the results of studies that
investigated extract from willow bark to Salix alba (White
willow); however, the proprietary extract investigated in these
studies was obtained from Salix purpurea (Purple willow)
[17, 18]. According to the WHO guideline (http://apps.who
.int/medicinedocs/en/d/Jh2984e/), herbal medicines are de-
fined as being finished, labeled medicinal products that
contain as active ingredients aerial or underground parts
of plants, or other plant material, or combinations thereof,
whether in the crude state or as plant preparations.
Plant materials combined with chemically defined active
substances (synthetic or isolated constituents of plants) are
not considered to be herbal medicines; however, this strin-
gent definition of herbal medicines appears only to have
been applied to very recent Cochrane reviews on herbal
medicines [19, 20]. For example, a study investigating an
ointment containing isolated or synthetic compounds—ethy
salicylate, methyl salicylate, glycosalicylate, salicylic acid,
camphor,menthol in addition to capsicumoleoresin—should
not have been included in the review of herbal medicine
for low back pain [5]. Likewise, single ingredients (e.g., the
alkaloid berberine [6] or policosanol [13] or the mixture of
ispaghula husk and a lipase inhibitor [21]) are not defined
as herbal medicines and should be excluded from reviews
on herbal medicines for type 2 diabetes, hypercholestero-
laemia, and IBS. Further, some Chinese herbal medicines
may not solely derive from plants; they may also contain
animal products or minerals [7]. We recommend that the
Cochrane Collaboration stipulate that studies of such mixed
preparations be handled independently, respecting theWHO
definition of herbal medicines.
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Table 2: The eleven most relevant Cochrane reviews on herbal medicines extracted for confirmatory study design, ITT analysis, study
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In case of 5-year studies; ∗∗disease-related death/total recruited patients × 100%.
4.2. Plausibility of Study Medications. For many medicinal
plant parts, the qualitative and quantitative content of
ingredients is known, as well as the effects these ingredients
produce. An analysis of the plausibility for using particular
medicinal plant parts for particular indications is notably
absent from all eleven Cochrane reviews considered in
this project. For example, one of the trials in the review
on IBS investigated a decoction of Senna leaf, which was
administered together with fluoxetine daily, and clonazepam
1 tablet before bed, over 15 days [22]. Folium sennae is
included in the official monographs of the EMA. This
medicinal plant part is recommended for short-term use in
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cases of occasional constipation, and only if a therapeutic
effect cannot be achieved by a change of diet or the
administration of bulk forming agents (http://www.ema
.europa.eu/docs/en GB/document library/Herbal - Com-
munity herbal monograph/2009/12/WC500018215.pdf).
The EMA monograph recommends that the daily dose
of folium sennae should contain no more than 30mg of
hydroxyanthracene glycosides (calculated as sennoside B).
This dose is usually contained in 2 g dried leaf (http://www
.mdidea.com/products/new/new04009.html); participants in
that study received three times the “occasional constipation”
dose in order to reduce IBS complaints [22]. Such high doses
are associated with intolerable and inacceptable adverse
events (see section adverse events). We maintain that this
study should not have been included in the review on IBS
due to a probably inappropriate use of a herbal medicine,
and poor reporting of potential interactions, side effects, and
adverse events.
An additional example is the Chinese herbal medicine
“Xuezhikang” [13]. Eighteen studies investigated the effect
of “Xuezhikang” on elevated serum cholesterol but no
information has been provided explaining the rationale
behind this medication. An internet search of public domain
resources allowed us to identify that “Xuezhikang” is the
ethanolic extract of red yeast rice, a processed product of
yeast (Monascus purpureus) grown on rice (http://www
.naturalstandard.com/index-abstract.asp?create-abstract=
redyeast.asp&title=Red%20yeast%20rice). The product con-
tains several compounds collectively known as monacolins,
substances that inhibit cholesterol synthesis. One of these,
monacolin K, has the same chemical structure as the drugs
lovastatin and mevinolin, potent inhibitors of HMG-CoA
reductase (http://www.naturalstandard.com/index-abstract
.asp?create-abstract=redyeast.asp&title=Red%20yeast%20
rice). We argue that this information should have been
included in the Cochrane review as part of the rationale for
the intervention.
In short, in cases where the active principle of the herbal
medicine is not known, we suggest that Cochrane reviews
should incorporate a table with co-active ingredients and
their known effects and/or discuss the plausibility of the study
medication.
4.3. Completeness of the Reviews. Some of the reviews might
be considered incomplete. For example, the Cochrane review
on IBS included preparations from single plant parts only.
Reasons for not including the clinical trials using extracted
volatile oil ofMentha piperitum [23] or with other medicinal
plant products (e.g., extracts from Hypericum perforatum or
Curcuma longa [24] or psyllium (ispaghula seed or husk))
were not stated.
Ispaghula seed is the dried ripe seed of Plantago ovata.
The ratio of soluble (mucilagemucopolysaccharides) to insol-
uble fibres is 47 : 53. The ESCOP monograph recommends
for the treatment of constipation or irritable bowel syndrome
in adults and children older than 12 years a daily dose of
7 to 30 g [25]. The episperm and collapsed layers from the
seeds of Plantago ovata, the ispaghula seed husk, may be used
instead in a dose of 4 to 20 g per day [26]. In a dose-finding
study [27], 20 g ispaghula seed huskwas identified as possibly
optimum daily dosage for treating IBS complaints. Lower
doses were less effective. Only one of the clinical trials [28]
included in the Cochrane review on bulking agents for IBS
[29] studied a daily dose of 20 g of the husk. Ruepert and
colleagues’ general conclusion that there is no evidence that
bulking agents are effective for treating IBS is not justified
unless the optimumdose for soluble fibres for the relief of IBS
complaints has been predetermined. Unfortunately, the most
recent trial investigating psyllium seed was also underdosed
at 10 g of psyllium per day [30].
Further, another Cochrane review on the effectiveness
of artichoke leaf extract for treating hypercholesterolaemia
[31] had identified 3 clinical trials. Only one of these stud-
ies has been considered in the review by Liu et al. [13].
Rationale for excluding the study by Englisch et al. [32]
was given as “lack of randomisation,” but identifying this
study as nonrandomised might not be justified because this
study was conducted in Germany where the International
Conference on Harmonisation Good Clinical Practice (ICH
GCP) guidelines were recommended from 1986 onwards and
constituted in 1989. It could be assumed that a study carried
out in 1996 with ethics committee approval was compliant
with the ICH guidelines regarding randomisation, allocation
concealment, and blinding of participants and assessors. For
this reason this same study was included in the Cochrane
review by Wider et al. [31]. (Wider, and at least 2 of her
colleagues, are German, and completely au fait with the
German law.) The evidence of effectiveness of artichoke leaf
extract for hypercholesterolaemia was, thus, underreported
in the review by Liu et al. [13].
4.4. Exploratory Studies and Effect Sizes. Typically, effect sizes
are calculated for all studies included in Cochrane reviews.
Hypotheses and sample size calculations are proposed items
of the CONSORT checklist [2]. Only studies with a confirma-
tory study design that consider possible confounders in their
analysis demonstrate efficacy. Exploratory studies are likely
to be underpowered and at increased risk of Type II error;
thuswe recommend that effect sizes are reported so that likely
effects will not be overlooked. Effect sizes from exploratory
studies present numbers that cannot be relied upon to predict
clinical outcomes, but they are helpful in calculating sample
sizes for future confirmatory studies.Only 3 of the 209 clinical
trials had hypotheses, and none of these were stated in the
articles. It remains unclear if the hypotheses were clinically
relevant.
4.5. Putative Adverse Events and Interactions. Although
major adverse events did not occur in any of the short-term
clinical trials, putative adverse events could be discussed in
light of the fact that the herbal medicines may be taken
over longer times than investigated. The study medication
“Daming,” for example, will have a laxative effect. Daming
could be standardized on the total anthraquinone content,
or its main marker compound chrysophanol [16], but the
total anthraquinone content in the daily “Daming” dosage
was not stated. Because anthraquinone derivatives are toxic
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compounds [33, 34], and sage contains toxic monoterpenes
[35], we maintain that a warning should have been included
in the review not to use “Daming” for long-term treatment.
The ESCOP monograph limits use of oral sage (infusions of
3 g) to up to 4 weeks.
Adverse events were not reported in the study inves-
tigating Senna leaf for IBS [21]. Senna leaf may produce
abdominal pain and spasm and passage of liquid stools,
in particular in patients with irritable colon. It may well
be that the patients received clonazepam concomitantly to
treat the putative abdominal complaints. Also, details of
patients’ concomitant medications for other diseases were
not reported in this study. Hypokalaemia resulting from
long-term laxative abuse (i.e., more than 15 days continuous
use of the EMA recommended dose of Senna leaf) may
potentiate the action of cardiac glycosides and interact with
antiarrhythmic medicinal products (prescribed to induce
reversion to sinus rhythm, e.g., quinidine, or prolong QT-
phase). Concomitant use of Senna leaf preparations and other
medicinal products inducing hypokalaemia (e.g., diuretics,
adrenocorticosteroids, and liquorice root) may disturb elec-
trolyte balance.
Further, the Cochrane review on St. John’s wort for
depression [36] did not raise the importance of the hyperforin
content in medicinal plant products. Hyperforine is the
Hypericum ingredient which is related to St. John’s wort drug
interactions [37].
5. Conclusion
Cochrane reviews on herbal medicines should make trans-
parent exactly what was studied and allow readers to accu-
rately compare studies. We suggest that the reviews should
report a table of detailed study medication characteristics
including the Latin names of the plants, the plant parts, the
preparation investigated (crude drug, extract, and if extract
drug extract ratio and solvent), and daily dose. If known,
then further details, such as the proprietary product or
extract name, the manufacturer, and the daily dose of marker
substance(s), should be added to improve the repeatability
of studies. Formulae changes of herbal mixtures differ in
their active principles from the original formulations, and
should be handled as separate medications. Studies with
single compounds ormixtureswith nonherbal entities should
be excluded from reviews on herbal medicines.
Plausibility for the choice of the plant part(s) and the dose
with respect to the medical indication should be checked.
Effect sizes calculated from exploratory studies are best
used to determine sample sizes required in planning future
confirmatory studies. In the interest of clinical safety, we
recommend that putative adverse events and possible inter-
actions also be discussed. In at least some Cochrane reviews
on herbal medicine the best available research evidence could
be improved to maintain the claim that Cochrane reviews are
the gold standard for evidence-based medicine. We hope our
discussion, as well as proposals and annotations, stimulate re-
thinking of the guidelines for the preparation of Cochrane
reviews of herbal medicines in order to make them more
transparent and useful for health care providers, policy-
makers, and patients and their advocates and carers.
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